drugset / Trial / NCT01617590
Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research
RandomizedParallel-groupOpen-labelTreatment
Summary
This study was intended to assess the efficacy and safety of different Disease-Modifying Antirheumatic Drugs cycle combination regimen using the American College of Rheumatology (ACR) criteria of 20% improvement in symptoms (ACR20) in managing active adult rheumatoid arthritis.
Timeline
- Start
- 2012-05
- Primary completion
- 2013-12
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leflunomide | Small molecule | 10 mg | Oral |
| Subject | Leflunomide | Small molecule | 20 mg | Oral |
| Comparator | Methotrexate | Small molecule | 7.5 mg | Oral |
| Comparator | Methotrexate | Small molecule | 15 mg | Oral |